Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yi Meng Chang"'
Autor:
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Abstract Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432
Externí odkaz:
https://doaj.org/article/c127bbfa3a4040329f269c6323da0d06
Autor:
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Niemann, Anthony Schwarer, Javier Loscertales Pueyo, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
HemaSphere, Vol 7, p e064430a (2023)
Externí odkaz:
https://doaj.org/article/69b7c9662b2f4c66bf1d9a50ff0a94d2
Autor:
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/c77836ed356f4db6a5fa3d2f59504785
Autor:
Mark P. Hertzberg, Jamie Hirata, Gilles Salles, Laurie H. Sehn, Muhit Ozcan, Grace Ku, Christopher R. Flowers, Alex F. Herrera, Andrew McMillan, Tae Min Kim, Stephen Opat, Lisa Musick, Yi Meng Chang, Violaine Safar, Matthew J. Matasar, Sarit Assouline
Publikováno v:
Blood Advances
Key Points Consistent with previous results, pola + BR has a tolerable safety profile.The survival benefit of pola + BR vs BR persists with longer follow-up; efficacy in the pola + BR extension and randomized arms was similar.
Visual Abstract
Visual Abstract
Autor:
Matthew Wongchenko, Hussein Abdul-Hassan Tawbi, Omid Hamid, Karl D. Lewis, Yibing Yan, Genevive Hernandez, Marcus Ballinger, Patrick Hwu, Rene Gonzalez, Jeffrey R. Infante, F. Stephen Hodi, Edward Cha, Manish R. Patel, Ryan J. Sullivan, Louise Roberts, Yi Meng Chang
Publikováno v:
Nature Medicine. 25:929-935
Melanoma treatment has progressed in the past decade with the development and approval of immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4, as well as small molecul
Autor:
Matthew J. Matasar, Corinne Haioun, Juan-Manuel Sancho, Andreas Viardot, Antonia Rodriguez Izquierdo, Eva Maria Donato Martin, Alejandro Martin Garcia-Sancho, Jose David Sandoval-Sus, Herve Tilly, Elizabeth Vandenberghe, Jamie Hirata, Priya Choudhry, Yi Meng Chang, Lisa Musick, Andrew McMillan
Publikováno v:
Journal of Clinical Oncology. 40:7551-7551
7551 Background: Transplant-ineligible pts with R/R DLBCL have a poor prognosis (Gisselbrecht C, et al. Br J Haematol 2018). Several treatment options are available including platinum-based chemotherapies such as oxaliplatin plus rituximab and gemcit
Autor:
Yanwen Jiang, Andrew McMillan, Pau Abrisqueta, Fiona Miall, Catherine Diefenbach, Yi Meng Chang, Lisa Musick, Lalita Banerjee, Jamie Hirata, Raul Cordoba, John M. Burke, Brad S. Kahl, Joseph N. Paulson, Javier Briones
Publikováno v:
Lancet Haematology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Obinutuzumab with polatuzumab vedotin or lenalidomide showed tolerability and activity in phase 1b/2 trials that recruited patients with relapsed or refractory follicular lymphoma. We aimed to examine whether the novel polatuzumab vedotin-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c47387aaa3eea0aa61f3886191daf60
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5259
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5259
Autor:
Katerina Hatzi, Mark Yan, Vibha Raghavan, Joseph N. Paulson, Tina Nielsen, Christian Klein, Yi Meng Chang, Estella Dong
Publikováno v:
Blood. 136:29-30
Introduction: The lymphoma microenvironment is increasingly recognized as crucial to sustaining lymphoma cell growth and an important contributor to treatment outcome, especially in the context of immunotherapies. CD20-targeted monoclonal antibodies
Autor:
Yi-Meng Chang, 張義孟
95
As the prompt development of Internet and digital still camera (DSC), still image is broadly used as storage and transmission contents. JPEG2000 is a relatively new still image compression standard. It has better compression performance than
As the prompt development of Internet and digital still camera (DSC), still image is broadly used as storage and transmission contents. JPEG2000 is a relatively new still image compression standard. It has better compression performance than
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/90873947851267563124